Surrogate markers of intestinal dysfunction associated with survival in advanced cancers
Deviations in the diversity and composition of the gut microbiota are called “gut dysbiosis”. They have been linked to various chronic diseases including cancers and resistance to immunotherapy. Stool shotgun based-metagenomics informs on the ecological composition of the gut microbiota and the prev...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2025.2484880 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850151073829879808 |
|---|---|
| author | Roxanne Birebent Damien Drubay Carolina Alves Costa Silva Federica Marmorino Giacomo Vitali Gianmarco Piccinno Yoan Hurtado Adele Bonato Lorenzo Belluomini Meriem Messaoudene Bertrand Routy Marine Fidelle Gerard Zalcman Julien Mazieres Clarisse Audigier-Valette Denis Moro-Sibilot François Goldwasser Arnaud Scherpereel Hervé Pegliasco François Ghiringhelli Anna Reni Fabrice Barlesi Laurence Albiges David Planchard Stéphanie Martinez Benjamin Besse Nicola Segata Chiara Cremolini Laurence Zitvogel Valerio Iebba Lisa Derosa |
| author_facet | Roxanne Birebent Damien Drubay Carolina Alves Costa Silva Federica Marmorino Giacomo Vitali Gianmarco Piccinno Yoan Hurtado Adele Bonato Lorenzo Belluomini Meriem Messaoudene Bertrand Routy Marine Fidelle Gerard Zalcman Julien Mazieres Clarisse Audigier-Valette Denis Moro-Sibilot François Goldwasser Arnaud Scherpereel Hervé Pegliasco François Ghiringhelli Anna Reni Fabrice Barlesi Laurence Albiges David Planchard Stéphanie Martinez Benjamin Besse Nicola Segata Chiara Cremolini Laurence Zitvogel Valerio Iebba Lisa Derosa |
| author_sort | Roxanne Birebent |
| collection | DOAJ |
| description | Deviations in the diversity and composition of the gut microbiota are called “gut dysbiosis”. They have been linked to various chronic diseases including cancers and resistance to immunotherapy. Stool shotgun based-metagenomics informs on the ecological composition of the gut microbiota and the prevalence of homeostatic bacteria such as Akkermansia muciniphila (Akk), while determination of the serum addressin MAdCAM-1 instructs on endothelial gut barrier dysfunction. Here we examined patient survival during chemo-immuno-therapy in 955 cancer patients across four independent cohorts of non-small cell lung (NSCLC), genitourinary (GU) and colorectal (CRC) cancers, according to hallmarks of gut dysbiosis. We show that Akk prevalence represents a stable and favorable phenotype in NSCLC and CRC cancer patients. Over-dominance of Akk above the healthy threshold was observed in dismal prognosis in NSCLC and GU and mirrored an immunosuppressive gut ecosystem and excessive intestinal epithelial exfoliation in NSCLC. In CRC, the combination of a lack of Akk and low sMAdCAM-1 levels identified a subset comprising 28% of patients with reduced survival, independent of the immunoscore. We conclude that gut dysbiosis hallmarks deserve integration within the diagnosis toolbox in oncological practice. |
| format | Article |
| id | doaj-art-6e73f92ec26c4a38b2dec9ee53460236 |
| institution | OA Journals |
| issn | 2162-402X |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | OncoImmunology |
| spelling | doaj-art-6e73f92ec26c4a38b2dec9ee534602362025-08-20T02:26:23ZengTaylor & Francis GroupOncoImmunology2162-402X2025-12-0114110.1080/2162402X.2025.2484880Surrogate markers of intestinal dysfunction associated with survival in advanced cancersRoxanne Birebent0Damien Drubay1Carolina Alves Costa Silva2Federica Marmorino3Giacomo Vitali4Gianmarco Piccinno5Yoan Hurtado6Adele Bonato7Lorenzo Belluomini8Meriem Messaoudene9Bertrand Routy10Marine Fidelle11Gerard Zalcman12Julien Mazieres13Clarisse Audigier-Valette14Denis Moro-Sibilot15François Goldwasser16Arnaud Scherpereel17Hervé Pegliasco18François Ghiringhelli19Anna Reni20Fabrice Barlesi21Laurence Albiges22David Planchard23Stéphanie Martinez24Benjamin Besse25Nicola Segata26Chiara Cremolini27Laurence Zitvogel28Valerio Iebba29Lisa Derosa30Gustave Roussy Cancer Campus, ClinicObiome, Villejuif, FranceGustave Roussy Cancer Campus, ClinicObiome, Villejuif, FranceGustave Roussy Cancer Campus, ClinicObiome, Villejuif, FranceUnit of Medical Oncology 2, University Hospital of Pisa, Pisa, ItalyGustave Roussy Cancer Campus, ClinicObiome, Villejuif, FranceDepartment CIBIO, University of Trento, Trento, ItalyGustave Roussy Cancer Campus, ClinicObiome, Villejuif, FranceGustave Roussy Cancer Campus, ClinicObiome, Villejuif, FranceGustave Roussy Cancer Campus, ClinicObiome, Villejuif, FranceCentre Hospitalier de l’Université de Montréal (CHUM), Hematology-Oncology Division, Department of Medicine, Montréal, QC, CanadaCentre Hospitalier de l’Université de Montréal (CHUM), Hematology-Oncology Division, Department of Medicine, Montréal, QC, CanadaGustave Roussy Cancer Campus, ClinicObiome, Villejuif, FranceThoracic Oncology Department-CIC1425/CLIP2 Paris-Nord, Bichat-Claude Bernard Hospital, AP-HP, Université Paris Cité, Paris, FranceService de Pneumologie, Centre Hospitalier Universitaire de Toulouse, Toulouse, FrancePneumology Department, Centre Hospitalier Toulon Sainte-Musse, Toulon, FranceDepartment of Thoracic Oncology, Centre Hospitalier Universitaire, Grenoble, FranceINSERM U1016-CNRS UMR8104-Cochin Institute, Université Paris-Cité, Paris,FranceDepartment of Pulmonary and Thoracic Oncology, University of Lille, University Hospital (CHU), INSERM unit OncoThAI, Lille, FrancePulmonary Department, European Hospital, Marseille, FranceCancer Biology Transfer Platform, Centre Georges-François Leclerc, Dijon, FranceGustave Roussy Cancer Campus, ClinicObiome, Villejuif, FranceGustave Roussy Cancer Campus, ClinicObiome, Villejuif, FranceGustave Roussy Cancer Campus, ClinicObiome, Villejuif, FranceGustave Roussy Cancer Campus, ClinicObiome, Villejuif, FranceService des Maladies Respiratoires, Centre Hospitalier d’Aix-en-Provence, Aix-en-Provence, FranceGustave Roussy Cancer Campus, ClinicObiome, Villejuif, FranceDepartment CIBIO, University of Trento, Trento, ItalyUnit of Medical Oncology 2, University Hospital of Pisa, Pisa, ItalyGustave Roussy Cancer Campus, ClinicObiome, Villejuif, FranceGustave Roussy Cancer Campus, ClinicObiome, Villejuif, FranceGustave Roussy Cancer Campus, ClinicObiome, Villejuif, FranceDeviations in the diversity and composition of the gut microbiota are called “gut dysbiosis”. They have been linked to various chronic diseases including cancers and resistance to immunotherapy. Stool shotgun based-metagenomics informs on the ecological composition of the gut microbiota and the prevalence of homeostatic bacteria such as Akkermansia muciniphila (Akk), while determination of the serum addressin MAdCAM-1 instructs on endothelial gut barrier dysfunction. Here we examined patient survival during chemo-immuno-therapy in 955 cancer patients across four independent cohorts of non-small cell lung (NSCLC), genitourinary (GU) and colorectal (CRC) cancers, according to hallmarks of gut dysbiosis. We show that Akk prevalence represents a stable and favorable phenotype in NSCLC and CRC cancer patients. Over-dominance of Akk above the healthy threshold was observed in dismal prognosis in NSCLC and GU and mirrored an immunosuppressive gut ecosystem and excessive intestinal epithelial exfoliation in NSCLC. In CRC, the combination of a lack of Akk and low sMAdCAM-1 levels identified a subset comprising 28% of patients with reduced survival, independent of the immunoscore. We conclude that gut dysbiosis hallmarks deserve integration within the diagnosis toolbox in oncological practice.https://www.tandfonline.com/doi/10.1080/2162402X.2025.2484880Gut dysbiosisAkkermansiaMAdCAM-1biomarkerimmune checkpoint inhibitorschemotherapy |
| spellingShingle | Roxanne Birebent Damien Drubay Carolina Alves Costa Silva Federica Marmorino Giacomo Vitali Gianmarco Piccinno Yoan Hurtado Adele Bonato Lorenzo Belluomini Meriem Messaoudene Bertrand Routy Marine Fidelle Gerard Zalcman Julien Mazieres Clarisse Audigier-Valette Denis Moro-Sibilot François Goldwasser Arnaud Scherpereel Hervé Pegliasco François Ghiringhelli Anna Reni Fabrice Barlesi Laurence Albiges David Planchard Stéphanie Martinez Benjamin Besse Nicola Segata Chiara Cremolini Laurence Zitvogel Valerio Iebba Lisa Derosa Surrogate markers of intestinal dysfunction associated with survival in advanced cancers OncoImmunology Gut dysbiosis Akkermansia MAdCAM-1 biomarker immune checkpoint inhibitors chemotherapy |
| title | Surrogate markers of intestinal dysfunction associated with survival in advanced cancers |
| title_full | Surrogate markers of intestinal dysfunction associated with survival in advanced cancers |
| title_fullStr | Surrogate markers of intestinal dysfunction associated with survival in advanced cancers |
| title_full_unstemmed | Surrogate markers of intestinal dysfunction associated with survival in advanced cancers |
| title_short | Surrogate markers of intestinal dysfunction associated with survival in advanced cancers |
| title_sort | surrogate markers of intestinal dysfunction associated with survival in advanced cancers |
| topic | Gut dysbiosis Akkermansia MAdCAM-1 biomarker immune checkpoint inhibitors chemotherapy |
| url | https://www.tandfonline.com/doi/10.1080/2162402X.2025.2484880 |
| work_keys_str_mv | AT roxannebirebent surrogatemarkersofintestinaldysfunctionassociatedwithsurvivalinadvancedcancers AT damiendrubay surrogatemarkersofintestinaldysfunctionassociatedwithsurvivalinadvancedcancers AT carolinaalvescostasilva surrogatemarkersofintestinaldysfunctionassociatedwithsurvivalinadvancedcancers AT federicamarmorino surrogatemarkersofintestinaldysfunctionassociatedwithsurvivalinadvancedcancers AT giacomovitali surrogatemarkersofintestinaldysfunctionassociatedwithsurvivalinadvancedcancers AT gianmarcopiccinno surrogatemarkersofintestinaldysfunctionassociatedwithsurvivalinadvancedcancers AT yoanhurtado surrogatemarkersofintestinaldysfunctionassociatedwithsurvivalinadvancedcancers AT adelebonato surrogatemarkersofintestinaldysfunctionassociatedwithsurvivalinadvancedcancers AT lorenzobelluomini surrogatemarkersofintestinaldysfunctionassociatedwithsurvivalinadvancedcancers AT meriemmessaoudene surrogatemarkersofintestinaldysfunctionassociatedwithsurvivalinadvancedcancers AT bertrandrouty surrogatemarkersofintestinaldysfunctionassociatedwithsurvivalinadvancedcancers AT marinefidelle surrogatemarkersofintestinaldysfunctionassociatedwithsurvivalinadvancedcancers AT gerardzalcman surrogatemarkersofintestinaldysfunctionassociatedwithsurvivalinadvancedcancers AT julienmazieres surrogatemarkersofintestinaldysfunctionassociatedwithsurvivalinadvancedcancers AT clarisseaudigiervalette surrogatemarkersofintestinaldysfunctionassociatedwithsurvivalinadvancedcancers AT denismorosibilot surrogatemarkersofintestinaldysfunctionassociatedwithsurvivalinadvancedcancers AT francoisgoldwasser surrogatemarkersofintestinaldysfunctionassociatedwithsurvivalinadvancedcancers AT arnaudscherpereel surrogatemarkersofintestinaldysfunctionassociatedwithsurvivalinadvancedcancers AT hervepegliasco surrogatemarkersofintestinaldysfunctionassociatedwithsurvivalinadvancedcancers AT francoisghiringhelli surrogatemarkersofintestinaldysfunctionassociatedwithsurvivalinadvancedcancers AT annareni surrogatemarkersofintestinaldysfunctionassociatedwithsurvivalinadvancedcancers AT fabricebarlesi surrogatemarkersofintestinaldysfunctionassociatedwithsurvivalinadvancedcancers AT laurencealbiges surrogatemarkersofintestinaldysfunctionassociatedwithsurvivalinadvancedcancers AT davidplanchard surrogatemarkersofintestinaldysfunctionassociatedwithsurvivalinadvancedcancers AT stephaniemartinez surrogatemarkersofintestinaldysfunctionassociatedwithsurvivalinadvancedcancers AT benjaminbesse surrogatemarkersofintestinaldysfunctionassociatedwithsurvivalinadvancedcancers AT nicolasegata surrogatemarkersofintestinaldysfunctionassociatedwithsurvivalinadvancedcancers AT chiaracremolini surrogatemarkersofintestinaldysfunctionassociatedwithsurvivalinadvancedcancers AT laurencezitvogel surrogatemarkersofintestinaldysfunctionassociatedwithsurvivalinadvancedcancers AT valerioiebba surrogatemarkersofintestinaldysfunctionassociatedwithsurvivalinadvancedcancers AT lisaderosa surrogatemarkersofintestinaldysfunctionassociatedwithsurvivalinadvancedcancers |